The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: a randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes.

INTRODUCTION: Coeliac disease (CD) is an autoimmune condition characterised by gluten-induced intestinal inflammation, and observed at a 5-10 fold greater prevalence in type 1 diabetes. While universal screening for CD in patients with diabetes is frequently advocated, objective data is limited as to benefits on diabetes control, bone health or quality of life related to the adoption of a gluten-free diet (GFD) in the large proportion of patients with diabetes with asymptomatic CD. The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) study is a multicenter, randomised controlled trial to evaluate the efficacy and safety of a GFD in patients with type 1 diabetes with asymptomatic CD. METHODS AND ANALYSIS: Children and adults (8-45 years) with type 1 diabetes will be screened for asymptomatic CD. Eligible patients with biopsy-proven CD will be randomly assigned in a 1:1 ratio to treatment with a GFD for 1 year, or continue with a gluten-containing diet. The primary outcome will evaluate the impact of the GFD on change in glycated haemoglobin. Secondary outcomes will evaluate changes in bone mineral density, blood glucose variability and health-related quality of life between GFD-treated and the regular diet group over a 1-year period. The study was initiated in 2012 and has subsequently expanded to multiple paediatric and adult centres in Ontario, Canada. ETHICS AND DISSEMINATION: The findings from this study will provide high-quality evidence as to the impact of GFD treatment on glycaemic control and complications in asymptomatic children and adults with CD and type 1 diabetes. TRIAL REGISTRATION NUMBER: NCT01566110.

Physical activity interacts with adiposity in determining cardiometabolic risk in adolescents.

BACKGROUND: Moderate-to-vigorous physical activity (MVPA) has been negatively associated with cardiometabolic risk. We sought to determine if MVPA interacts with body-mass index (BMI) and waist circumference (WC) in determining cardiometabolic risk in adolescents. METHODS: This cross-sectional study included cardiometabolic risk (blood pressure [BP], nonfasting lipids) screening and a 7-day recall physical activity questionnaire in 4,104 adolescents (51% male; mean age: 14.6 ± 0.5 years old). WC- and BMI- percentiles were used to define anthropometric categories (including obese adolescents: 90th WC, 85th BMI). RESULTS: Obesity in adolescents was associated with lower levels of high-density lipoprotein (HDL cholesterol (Estimate [EST]: -0.28(0.07) mmol/L, p < .001) and higher non-HDL cholesterol (EST: +0.38(0.14) mmol/L, p = .008). Each additional day with 20 min of MVPA was associated with lower non-HDL cholesterol (EST: -0.014(0.005) mmol/L/days/week, p = .003), independent of anthropometric category. Each additional day with 20 min of MVPA was associated with an increased odds ratio (OR) for higher BP category in obese adolescents (OR: 1.055, 95% CI: 1.028-1.084, p < .001) and a lower odds ratio for higher BP category in presumably-muscular adolescents (OR: 0.968, 95% CI: 0.934-0.989, p = .005). CONCLUSIONS: An increase in MVPA was associated with an increased likelihood for higher BP category in obese adolescents. The dose-response relationship between physical activity and cardiometabolic risk needs to be evaluated in adolescents of varying anthropometry categories.

Sleep disturbance and cardiovascular risk in adolescents.

BACKGROUND: Evidence suggests that inadequate or disturbed sleep is associated with increased cardiovascular risk in adults. There are limited data on sleep quality and associated cardiovascular risk in children. METHODS: We obtained data on adolescents from the 2009/10 cycle of the Healthy Heart Schools' Program, a population-based cross-sectional study in the Niagara region of Ontario. Participants underwent measurements of cardiometabolic risk factors, including body mass index (BMI), lipid profile and blood pressure, and they completed questionnaires measuring sleeping habits and nutritional status. We assessed sleep disturbance using the sleep disturbance score derived from the Pittsburgh Sleep Quality Index. We explored associations between sleeping habits and cardiovascular risk factors. RESULTS: Among 4104 adolescents (51% male), the mean hours of sleep per night (± standard deviation) were 7.9 ± 1.1 on weeknights and 9.4 ± 1.6 on weekends. In total, 19% of participants reported their sleep quality as fairly bad or very bad on weeknights and 10% reported it as fairly bad or very bad on weekends. In the multivariable regression models, a higher sleep disturbance score was associated with increased odds of being at high cardiovascular risk (highest v. lowest tertile odds ratio [OR] 1.43 [95% confidence interval (CI) 1.16-1.77], p < 0.001), increased odds of hypertension (highest v. lowest tertile OR 1.44 [95% CI 1.02-2.05], p = 0.05) and increased odds of elevated non-high density lipoprotein cholesterol (highest v. lowest tertile OR 1.28 [95% CI 1.00-1.64], p = 0.05). The mean duration of sleep was not associated with these outcomes. INTERPRETATION: In healthy adolescents, sleep disturbance is associated with cardiovascular risk factor abnormalities. Intervention strategies to optimize sleep hygiene early in life may be important for the prevention of cardiovascular disease.